- Home
- IMTX vs AGIO Comparison
IMTX vs AGIO Comparison
Compare IMTX & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IMTX | AGIO |
|---|---|---|
| Founded | N/A | 2007 |
| Country | Germany | United States |
| Employees | 423 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | IMTX | AGIO |
|---|---|---|
| Price | $10.01 | $29.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $19.25 | ★ $36.63 |
| AVG Volume (30 Days) | 351.5K | ★ 761.1K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $43,011,000.00 |
| Revenue This Year | N/A | $103.08 |
| Revenue Next Year | $19.39 | $126.67 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.30 | $22.24 |
| 52 Week High | $12.41 | $46.00 |
Technical Indicators
Market Signals| Indicator | IMTX | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 50.18 | 53.62 |
| Support Level | $9.66 | $26.40 |
| Resistance Level | $10.64 | $29.49 |
| Average True Range (ATR) | 0.54 | 1.24 |
| MACD | 0.02 | 0.21 |
| Stochastic Oscillator | 40.23 | 64.33 |
Price Performance
Historical ComparisonAbout IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.